Phreesia is demonstrating a successful pivot toward profitability, with operating income swinging from a $19.4M loss in 2025Q1 to an $11.1M profit in 2027Q2, driven by SG&A efficiency. However, this progress is threatened by a significant gross margin compress...
Price trend, volume and key moving averages
Trailing total returns as of 10/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 2, 2026 | $0.03-64.7% vs $0.09 | $129M+0.3% vs $129M |
Q2 2026 May 27, 2026 | $0.05+150.0% vs $0.02 | $131M+0.7% vs $130M |
Q2 2026 Mar 30, 2026 | $0.02-67.4% vs $0.07 | $127M+0.2% vs $127M |
Q4 2025 Dec 8, 2025 | $0.10 vs -$0.00 | $120M+0.3% vs $120M |
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia's Michael Rasbury, VP of AccessOne Solutions, named to Becker's Hospital Review's 2026 Rising Stars: Healthcare Leaders Under 40 list.
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to TIME's list of the World's Top HealthTech Companies of 2026. This marks the second consecutive year Phreesia has been recognized on the list, which is developed in partnership with Statista to identify companies using technology to make healthcare more effective and accessible. The 2026 list recognizes companies worldwide across six health technology market segm.
Phreesia, Inc. (NYSE: PHR - Get Free Report) General Counsel Allison Hoffman sold 6,662 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $10.08, for a total value of $67,152.96. Following the transaction, the general counsel directly owned 266,574 shares in the company, valued at
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia's ProviderConnect audiences are now available in the DeepIntent Audience Marketplace.
Benchmark PHR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Phreesia, Inc. (PHR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.94 | $676.22M | 291.73 | 14.48% | 0.48% | 0.77% | — | |
| $1.73 | $127.47M | -0.68 | 1.48% | -90.61% | -129.71% | — | |
| $30.97 | $5.79B | 31.60 | 13.05% | 25.48% | 16.95% | — | |
| $3.36 | $1.16B | 39.39 | 0.57% | 2.07% | 2.61% | — | |
| $310.36 | $50.42B | 57.05 | 16.34% | 29.34% | 14% | — | |
| $20.78 | $1.53B | 6.30 | 18.52% | 80.56% | 30.03% | — |
Phreesia, Inc. (PHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Phreesia, Inc. (PHR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 2, 2026·SEC
May 27, 2026·SEC
May 11, 2026·SEC
Get notified when PHR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Phreesia, Inc. (PHR) stock FAQ — growth, dividends, profitability & financials explained
Phreesia, Inc. (PHR) reported $507.8M in revenue for fiscal year 2026. This represents a 536% increase from $79.8M in 2018.
Phreesia, Inc. (PHR) grew revenue by 14.5% over the past year. This is steady growth.
Yes, Phreesia, Inc. (PHR) is profitable, generating $10.4M in net income for fiscal year 2026 (0.5% net margin).
Phreesia, Inc. (PHR) has a return on equity (ROE) of 0.8%. This is below average, suggesting room for improvement.
Phreesia, Inc. (PHR) generated $78.5M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
